Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Construction of an Evidence Based Startegy for the Use of Renin Angiotensin Aldosterone System Blockers for Future Targeting of ACE2 in Treatment of COVID19

NCT05418361 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT05418361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05418361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Construction of an Evidence Based Startegy for the Use of Renin Angiotensin Aldosterone System Blockers for Future Targeting of ACE2 in Treatment of COVID19
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Completed
Start date
June 15, 2021
Completion date
February 20, 2022
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renin-angiotensin system